ASND Stock Analysis: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$230.83
-0.32 (-0.14%)
▼
5d:
+7.06%
30d:
-3.0%
90d:
+3.13%
BUY
HIGH Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ASND trading at deep discount. Market pricing in -8.1% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ASND trading at deep discount. Market pricing in -8.1% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$162.87
Based on -6.8% avg growth
INTRINSIC VALUE TODAY
$101.13
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $230.83, which is considered fair relative to its 30-day fair value range of $216.60 to $241.57. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.5) compared to its historical average (31.5). Remarkably, the market is currently pricing in an annual earnings decline of 8.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ASND is showing sideways momentum. The price is approaching resistance at $237.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ASND has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $293.26 (+27.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ASND is showing sideways momentum. The price is approaching resistance at $237.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ASND has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $293.26 (+27.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$216.60 -
$241.57
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.0% below Wall St target ($293.26)
Trading Range Analysis
30-Day Trading Range
$216.60 -
$241.57
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$203.80
Resistance Level
$237.00
Current Trend
Sideways
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.50
Wall Street Target
$293.26
(+27.0%)
Revenue Growth (YoY)
144.3%
Profit Margin
57.3%
Valuation Discount vs History
-8.1% cheaper
PE vs Historical
24.5 vs 31.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.1%
(market-implied from PE analysis)
1-Year Target
$212.13
(-8%)
2-Year Target
$194.95
(-16%)
3-Year Target
$179.16
(-22%)
3-Yr Target (if PE normalizes)
(PE: 25→32)
$230.36
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.5, Growth: -17.6%)
$168.28
(+-27%)
Base:
(SPY PE: 21.8, Growth: -17.6%)
$149.60
(-35%)
Bear:
(PE: 18.5, Growth: -17.6%)
$127.16
(-45%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 26.73 | Current EPS (TTM): $8.78
Bull Case
$276.99
(+20%)
Analyst growth 7.3%, PE expands to 29.4
Base Case
$251.81
(+9%)
Market implied 7.3%, PE stable at 26.7
Bear Case
$159.57
(-31%)
Severe decline -20.0%, PE contracts to 22.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.5 to 31.5
Stabilization Target:
$296.79
(+28.6%)
PE Expansion Potential:
+28.6%
Share & Embed Analysis
Last updated: June 18, 2026 8:31 PM ET
Data refreshes hourly during market hours. Next update: 9:31 PM
Data refreshes hourly during market hours. Next update: 9:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 57 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 52 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 45 HOLD |
